FDA clears Alvotech to make SIMLANDI drug substance in second Reykjavik suite for US supply

• FDA cleared added U.S. manufacturing capacity for SIMLANDI, Alvotech’s Humira biosimilar, enabling AVT02 drug substance output from a second Reykjavik suite.
• Move effectively doubles U.S.-eligible drug substance capacity, expanding supply flexibility for the U.S. market.
• Decision follows FDA’s July 2026 VAI classification for the Reykjavik facility, supporting action on other pending applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050400PRIMZONEFULLFEED1001276163) on October 05, 2026, and is solely responsible for the information contained therein.